Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Dietitian's plan help older pancreatic cancer patients feel better?

NCT ID NCT07821554

Symptom relief Sponsor: Inna Chen, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are testing whether personalised nutritional care from a trained dietitian improves quality of life for people aged 65 and older with pancreatic ductal adenocarcinoma. About 250 participants will be randomly assigned to either six months of individualised nutrition support or usual nutritional care. The study follows participants for 12 months and measures quality of life, weight, body composition, muscle strength, and physical function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Personalised nutritional care delivered by a trained dietitian, including dietary counselling, individual nutrition targets, and oral nutritional supplements when needed
What this could lead to
If it works, this could give older pancreatic cancer patients a structured way to maintain weight, muscle, and quality of life during treatment. It could also shape how cancer centres routinely support nutrition in this age group.
What could go wrong
Nutrition support may not be enough to counter the aggressive weight loss and muscle wasting that pancreatic cancer causes. The trial is open-label, so patients and dietitians know which group they are in, which can influence how people report their quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is 65 years or older at the time of signing informed consent. * Histologically or cytologically confirmed borderline resectable, locally advanced or metastatic pancreatic ductal adenocarcinoma. * Participant is managed at a participating oncology, surgical or gastroenterology site and is planned to start, or has recently started, an eligible PDAC treatment within 14 days. * ECOG performance status 0-2. * Signed informed consent before any study-specific procedure. Exclusion Criteria: * Expected life expectancy of less than 3 months, in the judgement of the investigator. * Unable to provide informed consent and no legally authorised representative procedure is applicable under local regulations. * Participation in another interventional nutrition trial or structured nutritional programme that would interfere with the NutriCa65 intervention or outcome assessments. * Known allergy, intolerance or contraindication to all available oral nutritional supplements or intervention products, where no suitable alternative can be provided. * Clinical condition making participation in trial procedures unsafe or excessively burdensome, as judged by the investigator. * Any other condition that, in the investigator's opinion, would compromise participant safety, rights or data integrity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dehydration malignant pancreatic neoplasm Malnutrition pancreatic ductal adenocarcinoma pancreatic neoplasm Sarcopenia Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Medical Oncology

    Bucharest, Romania

  • Department of Medical Oncology

    Madrid, Spain

  • Department of Medicine

    Bergen, Norway

  • Department of Oncology

    Herlev, 2730, Denmark

  • Department of Surgery, Oncology and Gastroenterology

    Padova, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.